Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
5
Neutral
7
Bullish
2
Bearish
14
Neutral
7
Bullish
25
Bearish
9
Neutral
0
Bullish
23
Bearish
5
Neutral
7
Bullish
2
Bearish
5
Neutral
7
Bullish
2
Bearish
9
Neutral
0
Bullish
23
Bearish
9
Neutral
0
Bullish
23
Bearish
9
Neutral
0
Bullish
23
Investor Presentation
Q1 FY26
Discovery themes featuring this stock
Dr. Agarwal's Health Care Limited is India's largest eye care service chain by revenue, providing comprehensive services like surgeries, consultations, and optical sales.
The company is undergoing a merger with Dr. Agarwal's Eye Hospital Limited, consolidating operations to enhance service delivery and market presence across India and Africa.
The proposed merger will involve a preferential allotment to finance significant capex, highlighting an aggressive expansion strategy over the next few years.
AHCL has demonstrated significant financial growth in FY25 with a 28.4% increase in revenue from operations, showcasing strong market demand and operational success.
Healthcare Services
Hospital
2,566 Cr
Low Risk
33.7
64.5
1.1
7.4
6,392.00
4,412.05
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
354.05 | 3,248 Cr | 17.27 | 4.39 | 1.13 | 24.80 | 32.39 | 18.96 | ||
5310.00 | 2,566 Cr | 33.67 | 7.41 | 0.08 | 20.24 | 15.63 | 9.94 | ||
139.00 | 2,261 Cr | 40.53 | 10.74 | 0.00 | 22.21 | 24.22 | 16.79 | ||
144.15 | 1,557 Cr | 41.51 | 1.55 | 0.00 | 3.72 | 6.20 | 2.04 | ||
171.10 | 1,347 Cr | 80.44 | 5.33 | 0.00 | 6.14 | 8.20 | 5.62 | ||
158.20 | 1,306 Cr | 27.64 | 4.85 | 1.57 | 15.67 | 16.97 | 10.17 | ||
712.00 | 1,132 Cr | 43.83 | 8.14 | 0.00 | 18.77 | 27.73 | 17.88 | ||
| Median: 7 Co. | — | 171.10 | 1,557 Cr | 40.53 | 5.33 | 0.00 | 18.77 | 16.97 | 10.17 |
Dr Agarwals Eye Hospital Ltd (DRAGARWQ) is currently trading at 5,310.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Dr. Agarwal's Health Care Limited is India's largest eye care service chain by revenue, providing comprehensive services like surgeries, consultations, and optical sales. The company is undergoing a merger with Dr. Agarwal's Eye Hospital Limited, consolidating operations to enhance service delivery and market presence across India and Africa. The proposed merger will involve a preferential allotment to finance significant capex, highlighting an aggressive expansion strategy over the next few years. AHCL has demonstrated significant financial growth in FY25 with a 28.4% increase in revenue from operations, showcasing strong market demand and operational success.
Over the past 52 weeks, Dr Agarwals Eye Hospital Ltd has traded between a low of ₹4,412.05 and a high of ₹6,392.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Dr Agarwals Eye Hospital Ltd has a market capitalization of approximately 2,566.23. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Dr Agarwals Eye Hospital Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 33.67 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,566.23 Cr, Dr Agarwals Eye Hospital Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Dr Agarwals Eye Hospital Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Dr Agarwals Eye Hospital Ltd is 33.67. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board meeting to consider and approve Q1 FY27 unaudited results is scheduled for August 4, 2026.
The board meeting to consider Q1 FY27 unaudited results is scheduled for August 4, 2026, and the earnings call is also on August 4, 2026 at 5:30 PM IST.
They approved the Scheme of Amalgamation between Dr Agarwal’s Health Care Limited (AHCL) and Dr Agarwal’s Eye Hospital Limited (AEHL).
The equity shareholder meeting is on July 02, 2026 at 9:00 AM IST, and the unsecured creditor meeting is on July 02, 2026 at 11:30 AM IST.
AGM/EGM Notice
Dr Agarwals Eye Hospital Ltd reports results of 32nd AGM e-voting with scrutinizer report; audited financials adopted and dividend of Rs.4.00 per share for FY ended Mar 31, 2026 declared.
AGM/EGM Notice
Dr Agarwal's Eye Hospital held its 32nd AGM on 2026-09-09 via VC; six resolutions passed including adoption of audited financials for FY2025-26, declaration of dividend, reappointment of director and remuneration revisions.
